Skip to main content
    Z

    Zimmer Biomet Holdings Inc (ZBH)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $101.44
    -1.78 (-1.72%)

    Market Cap: $19.53B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zimmer Biomet Holdings Inc (ZBH) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Zimmer Biomet Holdings (ZBH) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Zimmer Biomet Holdings reported EPS of $1.90, above the $1.89 estimate. It beat the EPS estimate in each of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +7.44%
    Streak
    8 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.51
    Range$2.39 - $2.67
    26 analysts
    Revenue Consensus
    $2.31B
    Range$2.23B - $2.42B
    25 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.08
    Range$2.00 - $2.18
    18 analysts
    EPS Revisions
    7
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$2.12-1.8%
    60d ago$2.12-1.8%
    30d ago$2.12-1.8%
    7d ago$2.11-1.4%
    Current$2.08
    Revenue Consensus
    $2.15B
    Range$2.12B - $2.17B
    13 analysts

    Next Report

    ZBH has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.7% above the $2.42 reported for the quarter ended Dec 31, 2025.

    ZBH Earnings Call

    The latest ZBH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ZBH beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $2.06B, up 3.0% from $2.00B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.90$1.89$1.86 - $1.91+0.53%Beat0.0%2412 up, 7 downNov 4, 2026$2.06B
    Jun 30, 2026$2.07$2.01$1.98 - $2.05+2.99%Beat0.0%240 up, 3 downAug 5, 2026$2.18B
    Mar 31, 2026$2.09$1.86$1.84 - $1.93+12.37%Beat+15.5%241 up, 1 downApr 28, 2026$2.09B
    Dec 31, 2025$2.42$2.40$2.35 - $2.45+0.83%Beat+4.8%241 up, 2 downFeb 10, 2026$2.24B
    Sep 30, 2025$1.90$1.88$1.72 - $1.95+1.06%Beat+9.2%242 up, 5 downNov 5, 2025$2.00B
    Jun 30, 2025$2.07$1.98$1.79 - $2.07+4.55%Beat+3.0%230 up, 2 downAug 7, 2025$2.08B
    Mar 31, 2025$1.81$1.77$1.71 - $1.92+2.26%Beat-6.7%253 up, 1 downMay 5, 2025$1.91B
    Dec 31, 2024$2.31$2.29$2.24 - $2.34+0.87%Beat+5.0%270 up, 4 downFeb 6, 2025$2.02B
    Sep 30, 2024$1.74$1.74$1.63 - $1.960.00%In line+5.5%260 up, 1 downOct 30, 2024$1.82B
    Jun 30, 2024$2.01$1.99$1.94 - $2.03+1.00%Beat+10.4%260 up, 0 downAug 7, 2024$1.94B
    Mar 31, 2024$1.94$1.87$1.80 - $1.92+3.74%Beat+2.6%251 up, 2 downMay 2, 2024$1.89B
    Dec 31, 2023$2.20$2.16$2.11 - $2.21+1.85%Beat+17.0%240 up, 0 downFeb 8, 2024$1.94B
    Sep 30, 2023$1.65$1.60$1.56 - $1.64+3.13%Beat+4.4%250 up, 0 downNov 7, 2023$1.75B
    Jun 30, 2023$1.82$1.81$1.76 - $1.91+0.55%Beat0.0%231 up, 0 downAug 1, 2023$1.87B
    Mar 31, 2023$1.89$1.64$1.45 - $1.70+15.24%Beat+17.4%251 up, 0 downMay 2, 2023$1.83B
    Dec 31, 2022$1.88$1.83$1.76 - $1.90+2.73%Beat-3.6%242 up, 0 downFeb 3, 2023$1.83B
    Sep 30, 2022$1.58$1.56$1.46 - $1.60+1.28%Beat-12.7%251 up, 1 downNov 2, 2022$1.67B
    Jun 30, 2022$1.82$1.64$1.58 - $1.75+10.98%Beat-4.2%230 up, 1 downAug 2, 2022$1.78B
    Mar 31, 2022$1.61$1.42$1.30 - $1.55+13.38%Beat-5.8%234 up, 0 downMay 3, 2022$1.66B
    Dec 31, 2021$1.95$1.98$1.90 - $2.08-1.52%Miss-7.6%271 up, 1 downFeb 7, 2022$1.78B
    Sep 30, 2021$1.81$1.76$1.65 - $1.87+2.84%Beat0.0%26N/ANov 4, 2021$1.69B
    Jun 30, 2021$1.90$1.86$1.81 - $2.02+2.15%Beat+3700.0%26N/AAug 3, 2021$1.76B
    Mar 31, 2021$1.71$1.53$1.26 - $1.77+11.76%Beat+0.6%27N/AMay 4, 2021$1.60B
    Dec 31, 2020$2.11$2.06$1.76 - $2.38+2.43%Beat-8.3%27N/AFeb 5, 2021$1.19B
    Sep 30, 2020$1.81$1.08$0.72 - $1.43+67.59%Beat+2.3%27N/ANov 6, 2020$1.93B
    Jun 30, 2020$0.05-$0.63-$1.32 - -$0.26+107.94%Beat-97.4%25N/AAug 4, 2020$1.23B
    Mar 31, 2020$1.70$1.47$0.05 - $1.89+15.65%Beat-9.1%18N/AMay 11, 2020$1.78B
    Dec 31, 2019$2.30$2.27$2.24 - $2.30+1.32%Beat+5.5%26N/AFeb 4, 2020$2.13B
    Sep 30, 2019$1.77$1.75$1.70 - $1.81+1.14%Beat+8.6%26N/ANov 5, 2019$1.89B
    Jun 30, 2019$1.93$1.91$1.85 - $1.94+1.05%Beat+0.5%28N/AJul 26, 2019$1.99B
    Mar 31, 2019$1.87$1.86$1.81 - $1.94+0.54%Beat-2.1%29N/AApr 26, 2019$1.98B
    Dec 31, 2018$2.18$2.17$2.12 - $2.21+0.46%Beat+3.8%30N/AFeb 1, 2019$2.07B
    Sep 30, 2018$1.63$1.60$1.56 - $1.69+1.88%Beat-5.2%27N/AOct 26, 2018$1.84B
    Jun 30, 2018$1.92$1.89$1.80 - $1.93+1.59%Beat-7.7%24N/AJul 27, 2018$2.01B
    Mar 31, 2018$1.91$1.89$1.83 - $2.13+1.06%Beat-10.3%26N/AApr 26, 2018$2.02B
    Dec 31, 2017$2.10$2.10$2.05 - $2.130.00%In line-1.9%25N/AJan 30, 2018$2.23B
    Sep 30, 2017$1.72$1.74$1.57 - $2.13-1.15%Miss-3.9%26N/ANov 1, 2017$1.76B
    Jun 30, 2017$2.08$2.10$2.07 - $2.13-0.95%Miss+3.0%26N/AJul 27, 2017$1.95B
    Mar 31, 2017$2.13$2.11N/A+0.95%Beat+6.5%N/AN/AApr 27, 2017$1.86B
    Dec 31, 2016$2.14$2.11N/A+1.42%Beat+2.4%N/AN/AJan 31, 2017$1.94B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $8.20, up 2.5% from the year before. It was $7.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$8.20+2.5%
    Dec 31, 2024$8.00+5.8%
    Dec 31, 2023$7.56+9.7%
    Dec 31, 2022$6.89-6.5%
    Dec 31, 2021$7.37+30.0%
    Dec 31, 2020$5.67-28.0%
    Dec 31, 2019$7.87+3.0%
    Dec 31, 2018$7.64-4.9%
    Dec 31, 2017$8.03+1.0%
    Dec 31, 2016$7.95N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,89417
    2026Q2Jun 30, 20268,32816
    2026Q1Mar 31, 20265,93919
    2025Q4Dec 31, 20259,06918
    2025Q3Sep 30, 20258,27317
    2025Q2Jun 30, 20258,46518
    2025Q1Mar 31, 20259,24819
    2024Q4Dec 31, 20249,34316

    2026Q3 Earnings Call

    Opening remarks

    David DeMartino Senior Vice President, Investor Relations Thank you, operator, and good morning, everyone. Welcome to Zimmer Biomet's Third Quarter 2026 Earnings Conference Call. Joining me on today's call are Ivan Tornos, our Chairman, President and CEO; and Paul Stellato, our Interim CFO and VP, Controller and Chief Accounting Officer. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. For a detailed discussion of all these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our SEC filings. Please note, we assume no obligation to update these forward-looking statements even if actual results or future expectations change materially. Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures are included within our third quarter earnings release, which can be found on our website, zimmerbiomet.com. With that, I'll turn the call over to Ivan. Ivan?

    Ivan Tornos Chairman, President and CEO Thank you, David. Good morning, everyone, and thank you for joining today's call. I would like to start, as I always do, by thanking the more than 17,000 global Zimmer Biomet team members for your commitment, your resilience and, most importantly, your dedication to serving our customers and their patients each and every day. I'm grateful to work alongside you, and I'm proud of the noble work we do to alleviate pain and improve the quality of life for people around the world. Roughly six months from now, we will be celebrating our 100-year anniversary as a company. And as I often tell all of you, we are just getting started. Our boldest chapter remains ahead. During my prepared remarks this morning, I'll cover three things. First, I'll review our third quarter performance. Second, I'll discuss our increased outlook for 2026. And third, I'll provide an update on our three strategic priorities, which remain the same: people and culture, operational excellence, and innovation and diversification. To begin, we delivered total net sales of $2.63 billion, resulting in 3.1% reported growth and 3.7% constant currency growth in the quarter compared to the third quarter of 2025. Excluding the negative impact of our China distributor network consolidation strategy, a one-time headwind in fiscal year 2026, our constant currency growth in the quarter would have been 4.7%.

    Frequently Asked Questions About ZBH

    When is Zimmer Biomet Holdings's next earnings date?

    Zimmer Biomet Holdings's next earnings report is expected for Feb 8, 2027.

    Did ZBH beat earnings estimates last quarter?

    Yes. Zimmer Biomet Holdings reported EPS of $1.90 for the quarter ended Sep 30, 2026, above the $1.89 estimate, a 0.53% surprise.

    What EPS do analysts expect from ZBH next quarter?

    The consensus EPS estimate for Zimmer Biomet Holdings for the quarter ending Dec 31, 2026 is $2.51 from 26 analysts, with estimates from $2.39 to $2.67.

    How often does ZBH beat earnings estimates?

    Zimmer Biomet Holdings beat the EPS estimate in each of the last 8 quarters, with an average surprise of +3.18%.